CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 153 enrolled
Drug / intervention
LY3556050 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04874636
NCT04874636Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Chronic Low Back Pain

Eli Lilly and Company·interventional·Posted May 6, 2021·Updated Nov 2, 2023

In Brief

A Phase 2 clinical trial evaluating LY3556050 and Placebo for Chronic Low-back Pain. Completed, enrolled 153 participants across 35 sites in 2 countries.

Detailed Summary

This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Low-back Pain
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMay 6, 2021
Enrollment StartMay 20, 2021
Primary CompletionFeb 9, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.2 years ago

Interventions

LY3556050drug

Administered orally

Placebodrug

Administered orally